Vesta
Approach
Company
Careers
News & Resources
Login
Contact
FEATURED
Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort
October 9, 2024
News & Resources
Latest News
Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort
October 2024
Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort
October 2024
Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers
Business Wire
May 2024
Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers
Business Wire
May 2024
Valar Labs debuts AI-powered cancer care prediction tool and secures $22M
TechCrunch
May 2024
Valar Labs debuts AI-powered cancer care prediction tool and secures $22M
TechCrunch
May 2024